By Fineline Cube 
Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced on September 8, 2026 the completion of its capital increase in Procapzoom, alongside the signing of a strategic cooperation agreement with the company. Upon closing of the transaction, Taienkang secured the exclusive commercial promotion service rights for SZ018 (MSCohiO Lens Project) — billed as the world‑first ocular surface cell therapy — in the China region.
Deal Milestone
| Item | Detail |
|---|---|
| Acquirer / Partner | Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) |
| Counterparty | Procapzoom |
| Transaction Type | Capital increase + strategic cooperation agreement |
| Key Right Obtained | Exclusive commercial promotion service rights for SZ018 in China |
| Product | SZ018 (MSCohiO Lens Project), Category 1 therapeutic biologic |
| Announcement Date | 8 Sep 2026 |
| Next Steps | Joint advancement of commercialization in severe ocular surface cell therapy |
Product Profile & Mechanism of Action
- Classification: Category 1 therapeutic biological product (China)
- Modality: Umbilical cord‑derived mesenchymal stem cells (MSCs) delivered via a silicone hydrogel carrier that enables stable retention of the cells on the ocular surface
- Safety Engineering: Cells undergo specialized processing to eliminate tumorigenic risk
- Innovation: Potentially overcomes existing treatment bottlenecks in immune‑related ophthalmic diseases, positioning SZ018 as a first‑of‑its‑kind approach in ocular surface cell therapy
Regulatory Status
| Item | Detail |
|---|---|
| Designation | FDA Orphan Drug Designation (ODD) |
| Indication | Chronic ocular graft‑versus‑host disease (coGVHD) |
| Granted | May 2023 |
| Significance | U.S. regulatory recognition supporting development for a rare, sight‑threatening complication of allogeneic stem cell transplantation |
Market Impact & Outlook
- China Ophthalmology Landscape: Immune‑related ocular surface diseases — including severe dry eye and ocular coGVHD — remain poorly served by existing therapies, creating demand for regenerative biologics.
- Strategic Positioning: The exclusive China commercialization rights extend Taienkang’s portfolio into advanced cell therapy, diversifying beyond its traditional pharmaceutical base.
- Commercialization Path: The partnership structure pairs Procapzoom’s development assets with Taienkang’s commercial infrastructure, a common route to accelerate market entry for Category 1 biologics in China.
- Global Validation: The FDA Orphan Drug Designation provides regulatory credibility that may support future overseas licensing and partnership opportunities.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding transaction completion, commercialization timelines, and regulatory development of SZ018. Actual results may differ due to risks including clinical trial outcomes, regulatory approval conditions, market adoption, and competitive dynamics.-Fineline Info & Tech